UniSuper Management Pty Ltd Increases Stock Position in IDEXX Laboratories, Inc. $IDXX

UniSuper Management Pty Ltd boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 23.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,564 shares of the company’s stock after purchasing an additional 1,624 shares during the quarter. UniSuper Management Pty Ltd’s holdings in IDEXX Laboratories were worth $5,471,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Blalock Williams LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $590,000. Arkadios Wealth Advisors purchased a new position in IDEXX Laboratories during the 2nd quarter worth $405,000. Orion Porfolio Solutions LLC lifted its stake in shares of IDEXX Laboratories by 116.6% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock worth $5,749,000 after acquiring an additional 5,770 shares during the period. USA Financial Formulas acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $2,381,000. Finally, Beacon Investment Advisory Services Inc. boosted its holdings in shares of IDEXX Laboratories by 15.7% in the third quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock valued at $35,932,000 after acquiring an additional 7,616 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $693.85 on Monday. The business has a 50 day moving average price of $705.83 and a 200 day moving average price of $656.34. The company has a market capitalization of $55.40 billion, a P/E ratio of 55.02, a PEG ratio of 3.71 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IDXX shares. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Morgan Stanley upped their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.